NAV

NCX 701

Identification

Generic Name
NCX 701
DrugBank Accession Number
DB05409
Background

Nitroparacetamol (NCX-701) is a newly synthesized nitric oxide-releasing derivative of paracetamol.

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 282.2494
Monoisotopic: 282.08518619
Chemical Formula
C12H14N2O6
Synonyms
Not Available
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Investigated for use/treatment in pain (acute or chronic).

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action

NCX-701 (nitroparacetamol) is a NO-releasing derivative of paracetamol (acetaminophen) that has shown potent antinociceptive and anti-inflammatory properties. NCX-701 induces a potent antinociceptive effect by a mechanism different from and complementary to that of paracetamol, and its action is mainly located within the spinal cord in monoarthritic animals.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenol esters. These are aromatic compounds containing a benzene ring substituted by a hydroxyl group and an ester group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenol esters
Sub Class
Not Available
Direct Parent
Phenol esters
Alternative Parents
Acetanilides / N-acetylarylamines / Phenoxy compounds / Fatty acid esters / Acetamides / Alkyl nitrates / Secondary carboxylic acid amides / Carboxylic acid esters / Organic nitro compounds / Organic nitric acids and derivatives
show 6 more
Substituents
Acetamide / Acetanilide / Alkyl nitrate / Allyl-type 1,3-dipolar organic compound / Anilide / Aromatic homomonocyclic compound / Carbonyl group / Carboxamide group / Carboxylic acid derivative / Carboxylic acid ester
show 21 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
F8Y1ZV5V9P
CAS number
Not Available
InChI Key
XTMOQAKCOFLCRZ-UHFFFAOYSA-N
InChI
InChI=1S/C12H14N2O6/c1-9(15)13-10-4-6-11(7-5-10)20-12(16)3-2-8-19-14(17)18/h4-7H,2-3,8H2,1H3,(H,13,15)
IUPAC Name
4-acetamidophenyl 4-(nitrooxy)butanoate
SMILES
CC(=O)NC1=CC=C(OC(=O)CCCO[N+]([O-])=O)C=C1

References

General References
  1. al-Swayeh OA, Futter LE, Clifford RH, Moore PK: Nitroparacetamol exhibits anti-inflammatory and anti-nociceptive activity. Br J Pharmacol. 2000 Aug;130(7):1453-6. [Article]
  2. Romero-Sandoval EA, Mazario J, Howat D, Herrero JF: NCX-701 (nitroparacetamol) is an effective antinociceptive agent in rat withdrawal reflexes and wind-up. Br J Pharmacol. 2002 Mar;135(6):1556-62. [Article]
PubChem Compound
6918532
PubChem Substance
175426996
ChemSpider
5293729

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0468 mg/mLALOGPS
logP1.24ALOGPS
logP1.23Chemaxon
logS-3.8ALOGPS
pKa (Strongest Acidic)14.68Chemaxon
pKa (Strongest Basic)-4.4Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area107.77 Å2Chemaxon
Rotatable Bond Count8Chemaxon
Refractivity68.9 m3·mol-1Chemaxon
Polarizability27.53 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.7858
Blood Brain Barrier+0.9711
Caco-2 permeable-0.5343
P-glycoprotein substrateNon-substrate0.7851
P-glycoprotein inhibitor INon-inhibitor0.809
P-glycoprotein inhibitor IINon-inhibitor0.9491
Renal organic cation transporterNon-inhibitor0.8415
CYP450 2C9 substrateNon-substrate0.7797
CYP450 2D6 substrateNon-substrate0.8028
CYP450 3A4 substrateSubstrate0.6365
CYP450 1A2 substrateNon-inhibitor0.5887
CYP450 2C9 inhibitorNon-inhibitor0.5094
CYP450 2D6 inhibitorNon-inhibitor0.8194
CYP450 2C19 inhibitorInhibitor0.5289
CYP450 3A4 inhibitorNon-inhibitor0.9309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.528
Ames testAMES toxic0.8249
CarcinogenicityNon-carcinogens0.6947
BiodegradationReady biodegradable0.9141
Rat acute toxicity2.7028 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5913
hERG inhibition (predictor II)Non-inhibitor0.9243
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0pc0-1900000000-63327ff0a8cd11a93a1e
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-183.1202832
predicted
DarkChem Lite v0.1.0
[M-H]-152.93697
predicted
DeepCCS 1.0 (2019)
[M+H]+184.4464832
predicted
DarkChem Lite v0.1.0
[M+H]+156.19704
predicted
DeepCCS 1.0 (2019)
[M+Na]+183.1518832
predicted
DarkChem Lite v0.1.0
[M+Na]+163.99132
predicted
DeepCCS 1.0 (2019)

Drug created at November 18, 2007 18:24 / Updated at June 12, 2020 16:52